申请人:Janssen Pharmaceutica NV
公开号:EP2308848A1
公开(公告)日:2011-04-13
This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to quinoline-derived amides that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
本发明涉及类香草素受体 VR1 配体。更具体地说,本发明涉及喹啉衍生酰胺,它们是 VR1 的强效拮抗剂或激动剂,可用于治疗和预防哺乳动物的炎症和其他疼痛病症。